This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CHS-131

Coherus BioSciences, Inc.

Drug Names(s): AMG 131, T131, T0903131, INT131

Description: INT131 is PPAR gamma selective modulator and partial agonist. PPAR gamma nuclear receptors regulate the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPAR gamma-responsive genes also participate in the regulation of fatty acid metabolism.

Animal studies of INT131 demonstrated greater potency and equal efficacy compared to Avandia, a marketed diabetes agent targeting PPAR gamma. INT131 caused less weight gain than Avandia in animal models.

Deal Structure: Amgen acquired T131 on August 13, 2004 through its acquisition of Tularik.

In January 2007, InteKrin Therapeutics entered into a license agreement with Amgen under which InteKrin has obtained worldwide development and commercialization rights to INT131.

Coherus and Intekrin
In February 2014, Coherus acquired InteKrin Therapeutics for total consideration of $5.0 million.

Partners: Amgen, Inc.


CHS-131 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug